Compounds > losoxantrone
Page last updated: 2024-11-06

losoxantrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

losoxantrone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72116
CHEMBL ID83520
SCHEMBL ID61319
MeSH IDM0144496

Synonyms (23)

Synonym
CHEMBL83520 ,
c-1941 ,
NCI60_003246
losoxantrone [inn:ban]
losoxantrone
anthrapyrazolone
anthra(1,9-cd)pyrazol-6(2h)-one, 7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)-
bdbm50240660
7-hydroxy-2-[2-(2-hydroxy-ethylamino)-ethyl]-5-[2-(2-hydroxy-ethylamino)-ethylamino]-2h-dibenzo[cd,g]indazol-6-one
bianthrazole
47kph00809 ,
88303-60-0
unii-47kph00809
anthra(1,9-cd)pyrazol-6(2h)-one, 7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)
7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)anthra(1,9-cd)pyrazol-6(2h)-one
losoxantrone [who-dd]
losoxantrone [inn]
SCHEMBL61319
DTXSID60236949
Q21098832
bianthrazole; biantrazole; c 1941; losoxantrone
7-hydroxy-2-[2-(2-hydroxyethylamino)ethyl]-5-[2-(2-hydroxyethylamino)ethylamino]anthra[1,9-cd]pyrazol-6(2h)-one
6-hydroxy-14-[2-(2-hydroxyethylamino)ethyl]-10-[2-(2-hydroxyethylamino)ethylamino]-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one

Research Excerpts

Overview

Losoxantrone is a DNA intercalator that was developed with the potential to replace anthracyclines.

ExcerptReferenceRelevance
"Losoxantrone is an anthrapyrazole derivative in Phase III development in the U.S. "( Elimination pathways of [14C]losoxantrone in four cancer patients.
Chai, MF; Davidson, AF; Finizio, M; Joshi, AS; Pieniaszek, HJ; Ratain, MJ; Richards, LE; Vogelzang, NJ; Vokes, EE, 2001)		2.04
"Losoxantrone is a DNA intercalator that was developed with the potential to replace anthracyclines. "( Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.
Goh, BC; Joshi, A; Ratain, MJ; Vokes, EE, 2002)		2.03

Toxicity

ExcerptReferenceRelevance
" Lethality studies in female Balb-c mice resulted in an LD10 value of 20 mg/kg (95% confidence limits; range, 19-21 mg/kg) and an LD50 value of 22 mg/kg (95% confidence limits; range, 21-23 mg/kg)."( The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.
Calvert, AH; Foster, BJ; Graham, MA; Newell, DR, 1989)		0.28

Pharmacokinetics

ExcerptReferenceRelevance
" More recently, the use of preclinical pharmacokinetic information in mice has been proposed to also provide information that might expedite early clinical trials and more specifically phase I studies."( Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalation.
Calvert, AH; Foster, BJ; Graham, MA; Gumbrell, LA; Jenns, KE; Kaye, SB; Newell, DR, 1992)		0.28
" A total of 37 patients received 74 courses of CI-941 (5 to 55 mg/m2), with 26 patients consenting to pharmacokinetic monitoring."( Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
Calvert, AH; Foster, BJ; Graham, MA; Gumbrell, LA; Jenns, KE; Newell, DR, 1992)		0.28

Dosage Studied

ExcerptRelevanceReference
" Several subsequent series suggest that with cumulative dosing of 360 mg/m2 doxorubicin, the rate of CHF can be reduced to approximately 5%."( Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer.
Kaufman, PA, 1999)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 2-alphaHomo sapiens (human)IC50 (µMol)7.30000.48004.35649.9400AID381809
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID381806Growth inhibition of human K562 cells after 72 hrs by MTS method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
AID107943In vivo antitumor activity at a single dose of 12.5 mg/kg & 37.5 mg/kg total against mammary adenocarcinoma 16C to assess tumor growth delay (T-C)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID381805Binding affinity to calf thymus DNA assessed as change in thermal stability at 2 uM in tris-HCl buffer at pH 7.5 by thermal denaturation assay2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
AID381809Inhibition of human topoisomerase 2alpha decantation activity2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
AID107947In vivo antitumor activity at a single dose of 12.5 mg/kg & 37.5 mg/kg total against mammary adenocarcinoma 16C1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID381807Growth inhibition of etoposide-resistant human K/VP.5 cells after 72 hrs by MTS method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
AID153901In vivo antitumor activity against P388 leukemia cells at a dose of 12.5 mg/kg (single injection) and 25 mg/kg (Total )1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID96628Antitumor activity against L1210 lymphocytic cells in vitro1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID381808Resistance factor, ratio of IC50 for etoposide-resistant human K/VP.5 cells to IC50 for human K562 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
AID107944In vivo antitumor activity at a single dose of 6.5 mg/kg & 18.8 mg/kg total against mammary adenocarcinoma 16C to assess tumor growth delay (T-C)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID107948In vivo antitumor activity at a single dose of 6.5 mg/kg & 18.8 mg/kg total against mammary adenocarcinoma 16C1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID153902In vivo antitumor activity against P388 leukemia cells at a dose of 25 mg/kg as a single injection and 50 mg/kg as a total1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (16.67)18.7374
1990's20 (55.56)18.2507
2000's9 (25.00)29.6817
2010's1 (2.78)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.91 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (17.50%)5.53%
Reviews2 (5.00%)6.00%
Case Studies1 (2.50%)4.05%
Observational0 (0.00%)0.25%
Other30 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		1.9610acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		1.9710aromatic ether;
nitrile;
polyether;
tertiary amino compound
hypericin
[no description available]		1.9910
metyrapone
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.		2.0110aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		2.940dihydroxyanthraquinoneanalgesic;
antineoplastic agent
pyrazolanthrone
pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.		210anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
perylene
Perylene: A 20-carbon dibenz(de,kl)anthracene that can be viewed as a naphthalene fused to a phenalene or as dinaphthalene. It is used as fluorescent lipid probe in the cytochemistry of membranes and is a polycyclic hydrocarbon pollutant in soil and water. Derivatives may be carcinogenic.. perylene : An ortho- and peri-fused polycyclic arene comprising of five benzene rings that is anthracene in which the d,e and k,l sides are fused to benzene rings.		1.9910ortho- and peri-fused polycyclic arene;
perylenes
neodymium
Neodymium: An element of the rare earth family of metals. It has the atomic symbol Nd, atomic number 60, and atomic weight 144.24, and is used in industrial applications.		1.9910f-block element atom;
lanthanoid atom
titanium
Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.		1.9910titanium group element atom
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		1.9710aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		10.1731taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		2.0410beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
piroxantrone
[no description available]		9.0140
asulacrine
asulacrine: derivative of amsacrine; structure given in first source		1.9610acridines
teloxantrone
teloxantrone: structure given in first source		3.7730
potassium titanylphosphate
[no description available]		1.9910
nadp
[no description available]		1.9710
sodium hypochlorite
Sodium Hypochlorite: It is used as an oxidizing and bleaching agent and as a disinfectant. (From Grant & Hackh's Chemical Dictionary, 5th ed). sodium hypochlorite : An inorganic sodium salt in which hypochlorite is the counterion. It is used as a bleaching and disinfecting agent and is commonly found in household bleach.		1.9910inorganic sodium saltbleaching agent;
disinfectant
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9610
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.3720
Benign Neoplasms
[description not available]		05.8164
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		05.8164
Innate Inflammatory Response
[description not available]		02.110
Endotoxin Shock
[description not available]		02.110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.110
Shock, Septic
Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.		02.110
B-Cell Lymphoma
[description not available]		02.0210
Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.		02.0210
Bone Cancer
[description not available]		03.7821
Breast Cancer
[description not available]		05.3851
Cardiac Failure
[description not available]		03.7821
Cancer of Lung
[description not available]		01.9810
Lymph Node Metastasis
[description not available]		01.9810
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		03.7821
Breast Neoplasms
Tumors or cancer of the human BREAST.		05.3851
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		03.7821
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9810
Carcinoma, Epidermoid
[description not available]		02.6830
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.6830
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9910
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9910
Cardiac Diseases
[description not available]		03.7721
Blood Pressure, High
[description not available]		01.9910
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		03.7721
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		01.9910
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		01.9910
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		04.3522
Experimental Neoplasms
[description not available]		01.9810
Metastase
[description not available]		04.7121
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		04.7121
Blood Diseases
[description not available]		03.3911
Cancer of Liver
[description not available]		03.3911
Cancer of Prostate
[description not available]		03.7921
Mucositis, Oral
[description not available]		03.3911
Emesis
[description not available]		03.3911
Anorexia
The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.		03.3911
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		03.3911
Hematologic Diseases
Disorders of the blood and blood forming tissues.		03.3911
Liver Neoplasms
Tumors or cancer of the LIVER.		03.3911
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		03.7921
Stomatitis
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.		03.3911
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		03.3911
Adenocarcinoma, Basal Cell
[description not available]		0210
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		0210
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		03.3911
Hepatoblastoma
A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)		02.0110
Bone Marrow Diseases
Diseases involving the BONE MARROW.		01.9810
Leukocytopenia
[description not available]		04.3322
Leukopenia
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).		04.3322
Absence Seizure
[description not available]		01.9710
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		01.9710
Experimental Leukemia
[description not available]		01.9710